Callan Family Office LLC Acquires New Stake in Stryker Co. (NYSE:SYK)

Callan Family Office LLC acquired a new position in shares of Stryker Co. (NYSE:SYK) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 4,406 shares of the medical technology company’s stock, valued at approximately $1,586,000.

Several other institutional investors have also recently added to or reduced their stakes in SYK. Kohmann Bosshard Financial Services LLC purchased a new stake in shares of Stryker during the fourth quarter worth about $25,000. Dunhill Financial LLC boosted its position in Stryker by 94.9% during the third quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock worth $27,000 after acquiring an additional 37 shares during the last quarter. Centricity Wealth Management LLC purchased a new stake in Stryker in the 4th quarter worth approximately $30,000. BankPlus Trust Department acquired a new position in Stryker in the 4th quarter valued at $33,000. Finally, Darwin Wealth Management LLC acquired a new position in Stryker in the 3rd quarter valued at $36,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Insider Activity

In other news, Director Allan C. Golston sold 2,458 shares of the stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total transaction of $941,586.06. Following the completion of the transaction, the director now directly owns 14,895 shares in the company, valued at approximately $5,705,827.65. This represents a 14.16 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Ronda E. Stryker sold 201,392 shares of the firm’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the sale, the director now directly owns 3,642,075 shares of the company’s stock, valued at $1,428,567,498. The trade was a 5.24 % decrease in their position. The disclosure for this sale can be found here. Insiders own 5.90% of the company’s stock.

Stryker Stock Performance

Shares of NYSE:SYK opened at $379.28 on Friday. The business’s 50-day simple moving average is $382.45 and its 200 day simple moving average is $372.78. The company has a market cap of $144.73 billion, a P/E ratio of 48.88, a PEG ratio of 2.93 and a beta of 0.96. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95. Stryker Co. has a one year low of $314.93 and a one year high of $406.19.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter last year, the company earned $3.46 EPS. On average, sell-side analysts forecast that Stryker Co. will post 13.47 earnings per share for the current fiscal year.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be given a $0.84 dividend. The ex-dividend date of this dividend is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a yield of 0.89%. Stryker’s payout ratio is currently 43.30%.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $442.00 price objective on shares of Stryker in a research report on Wednesday, January 29th. Truist Financial lifted their price target on Stryker from $409.00 to $413.00 and gave the company a “hold” rating in a report on Thursday, January 30th. JPMorgan Chase & Co. increased their price objective on shares of Stryker from $420.00 to $445.00 and gave the stock an “overweight” rating in a report on Wednesday, January 29th. StockNews.com cut shares of Stryker from a “buy” rating to a “hold” rating in a research report on Thursday. Finally, Citigroup reaffirmed a “buy” rating and set a $450.00 price target on shares of Stryker in a research report on Wednesday, February 26th. Five research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. According to data from MarketBeat.com, Stryker presently has an average rating of “Moderate Buy” and a consensus target price of $422.15.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.